Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical, a research-based pharmaceutical company located in Japan, has received approval for an additional indication of Takepron capsules 15 and Takepron OD tablets 15 for prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration, from the Ministry of Health, Labour and Welfare.
Subscribe to our email newsletter
Takepron is a proton pump inhibitor discovered by Takeda Pharmaceutical and has been launched since 1992 in Japan.
Takeda Pharmaceutical said that administration of low-dose aspirin for a long period sometimes causes gastric or duodenal ulcer, however, discontinuing of administration may make patients face a higher risk of forming blood clots and emboli. Therefore, it is considered that extended use of low-dose aspirin while preventing an onset of ulcers is important.
Takeda Pharmaceutical claimed that there have been no drugs which have an indication for prevention of ulcers during low-dose aspirin administration in Japan, it submitted an application for an additional indication of Takepron capsules 15 and Takepron OD tablets 15.
Yasuhiko Yamanaka, a member of the board, senior vice president of pharmaceutical marketing division at Takeda Pharmaceutical, said: “With the approval of this additional indication, we expect that Takepron helps patients who have a history of ulcers and take low-dose aspirin to prevent recurrence of ulcers.”